Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Grifols ( (ES:GRF) ) is now available.
Grifols has announced that its subsidiary, Grifols Biotest Holdings GmbH, has received approval from the German Federal Financial Supervisory Authority for its public acquisition offer to delist Biotest AG. The offer aims to acquire all ordinary and non-voting preferred shares of Biotest not already held by Grifols, with the acceptance period running until June 6, 2025. This strategic move is expected to strengthen Grifols’ position in the biopharmaceutical industry and could have significant implications for shareholders and market dynamics.
More about Grifols
Grifols is a global healthcare company specializing in the production of plasma-derived medicines and other innovative biopharmaceutical products. The company focuses on enhancing patient health and well-being through its extensive range of products and services.
YTD Price Performance: -6.65%
Average Trading Volume: 326,338
Technical Sentiment Signal: Strong Buy
Current Market Cap: €5.26B
See more data about GRF stock on TipRanks’ Stock Analysis page.